Teva responds ‘robustly’ to EU pay-for-delay charge

Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Report: 85% of in-house counsel want IP service providers to embrace AI

30 April 2026 Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.

Europe

Moderna loses key mRNA patent in European vaccine fight

30 April 2026 The company’s rivals convinced an EPO appeals board to revoke a patent that had been used in litigation against them over Comirnaty.

Europe

EU court under pressure to define SPC limits in patent row

24 April 2026 An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.

More features

WATCH: Interview with Ben Doranz, president and CEO, Integral Molecular

Brussels under scrutiny for IP policy as US flags risks to innovation

Squire Patton Boggs promotes partner to head Europe IP&T practice

From the courtroom: Hikma v Amarin SCOTUS oral arguments

Report: 85% of in-house counsel want IP service providers to embrace AI

Moderna loses key mRNA patent in European vaccine fight

Boston-based patent expert departs Mintz for major West Coast firm

Blow for Masimo’s fight with Apple as case against US Customs dismissed

Teva responds ‘robustly’ to EU pay-for-delay charge

More on this story

Editor's picks

Editor's picks

More features